ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Explore linked clinical trials.10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-07-07 | NCT07687914 | |
| A Study of IMM0306 in IgG4-Related Disease | Immunoglobulin G4-Related Disease, autoimmune disease, immune system disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-06-02 | NCT07621939 | |
| A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. | Arterial Occlusive Diseases, acute coronary syndrome, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Early phase 1 | 2026-04-15 | NCT06788431 | |
| IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 3 | 2026-01-27 | NCT07355283 | |
| A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women | Healthy Postmenopausal Women | Recruiting | Phase 1 | 2025-12-15 | NCT07118085 | |
| IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2025-11-25 | NCT06647862 | |
| A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2025-09-12 | NCT07170787 | |
| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors | hepatocellular carcinoma | Recruiting | Phase 1 | 2025-01-08 | NCT06764836 | |
| A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | non-small cell lung carcinoma | Not yet recruiting | Phase 2 | 2024-12-24 | NCT06746870 | |
| A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Not yet recruiting | Phase 3 | 2024-06-24 | NCT06465446 |